Bisamide CXCR4 Modulators: Novel Anti‐IBD Agents Acting on the Chemotaxis of Inflammatory Cells
Authors:
- 27 April 2022
- journal article
- research article
- Published by Wiley in Advanced Therapeutics
- Vol. 5 (6)
Abstract
Inflammatory bowel disease (IBD) is a chronic and recurrent inflammatory disease that with a relapsing and remitting course. There is an urgent demand for novel drugs to treat IBD with better efficacy and fewer side effects. CXCR4/CXCL12 axis plays a constitutive and inflammatory role in the intestinal mucosa, resulting in the chemotaxis of plenty of inflammatory cells to the intestine. Modulating this chemotactic axis by CXCR4 modulators may lead to the discovery of more effective anti‐IBD candidates. Taking the secondary amine as the lead structure, a series of bisamide CXCR4 modulators with various substituents are designed, synthesized, and evaluated for the ameliorating effects on acute inflammation and IBD. Among them, compound Im effectively alleviates TNBS‐induced IBD and reduces the number of inflammatory cells and the secretion of inflammatory factors in the intestinal mucosa. The obtained results indicate that CXCR4 is a potential anti‐IBD target, and design of potent CXCR4 modulators is an optional strategy to discover novel anti‐IBD candidates with different mechanisms.Keywords
Funding Information
- Natural Science Foundation of Zhejiang Province (LY20H300004)
- National Natural Science Foundation of China (81803340)
This publication has 20 references indexed in Scilit:
- Symmetrical bis-tertiary amines as novel CXCR4 inhibitorsEuropean Journal of Medicinal Chemistry, 2016
- AMD3100/CXCR4 InhibitorFrontiers in Immunology, 2015
- CXCL12 Is a constitutive and inflammatory chemokine in the intestinal immune systemInflammatory Bowel Diseases, 2010
- CXCR4 antagonist AMD3100 attenuates colonic damage in mice with experimental colitisWorld Journal of Gastroenterology, 2010
- Distinct Cytokine Patterns Identified from Multiplex Profiles of Murine DSS and TNBS-Induced ColitisInflammatory Bowel Diseases, 2009
- Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4The Journal of Immunology, 2009
- Discovery of Small Molecule CXCR4 AntagonistsJournal of Medicinal Chemistry, 2007
- AMD3100: CXCR4 Antagonist and Rapid Stem Cell-Mobilizing AgentFuture Oncology, 2007
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- CXCR4: chemokine receptor extraordinaireImmunological Reviews, 2000